Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 2

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 2
---
| Independent Registered Public Accounting Firm Fees and Other Matters                        |     | 14 |     |      |
| Executive Officers                                                                          |     | 15 |     |      |
| Corporate Governance                                                                        |     | 17 |     |      |
| Compensation Discussion and Analysis                                                        |     | 24 |     |      |
| Executive and Director Compensation                                                         |     | 40 |     |      |
| Security Ownership of Certain Beneficial Owners and Management                              |     | 50 |     |      |
| Certain Relationships                                                                       |     | 54 |     |      |
| Stockholders’ Proposals                                                                     |     | 55 |     |      |
| Other Matters                                                                               |     | 55 |     |      |
| Solicitation of Proxies                                                                     |     | 55 |     |      |
| Cartesian Therapeutics, Inc.’s Annual Report on Form 10-K                                   |     | 56 |     |      |

#### CARTESIAN THERAPEUTICS, INC.

#### 7495 New Horizon Way

#### Frederick, Maryland 21703

#### NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS

#### To be held June 13, 2025
The Annual Meeting of Stockholders (the “Annual Meeting”) of Cartesian Therapeutics, Inc., a Delaware corporation (the “Company”), will be held at 10:00 a.m., Eastern Time, on Friday, June 13, 2025, by virtual meeting online at www.virtualshareholdermeeting.com/RNAC2025 , for the following purposes:

1. To elect Timothy C. Barabe, M.B.A., Carsten Brunn, Ph.D., and Nishan de Silva, M.D., M.B.A. as Class III Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified;

2. To approve, on a non-binding and advisory basis, a resolution approving the compensation of our named executive officers, as described in the accompanying proxy statement under “Executive and Director Compensation”;

3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and

4. To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.

Holders of record of our common stock as of the close of business on April 14,